33 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
to align with our DEI goals each year. These goals include influencing our commitment to DEI through leadership and executive culture, fostering … that are in the best interests of our stockholders, our desire to foster a long-term commitment to our company, as well as the dilutive impact of equity
424B5
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Prospectus supplement for primary offering
4:53pm
appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis.
The distribution of the securities may be effected from time … with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby
424B3
2q8p0tr0in t79b5
8 Aug 22
Prospectus supplement
5:47pm
S-4
gh0 0bqlw
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
425
ap0lze9ar7qshjk6i
6 Jul 22
Business combination disclosure
4:30pm
8-K
EX-99.1
1bvhj4 g4ev19x7hh5
6 Jul 22
Other Events
4:27pm
425
4bx1oup
5 Jul 22
Business combination disclosure
7:14am
8-K
EX-99.1
bv9pn31
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
8-K
EX-2.1
s35rm6 jq0
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
424B5
tg8tma3c k90wrl3hxv
20 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
qp7bjg
19 Jan 21
Prospectus supplement for primary offering
4:06pm
8-K
EX-2.1
sx4svf 38p8hygxfsu
7 Dec 20
Entry into a Material Definitive Agreement
6:05am